- Home
- INTU vs AZN Comparison
INTU vs AZN Comparison
Compare INTU & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTU
- AZN
- Stock Information
- Founded
- INTU 1983
- AZN 1992
- Country
- INTU United States
- AZN United Kingdom
- Employees
- INTU N/A
- AZN N/A
- Industry
- INTU Computer Software: Prepackaged Software
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- INTU Technology
- AZN Health Care
- Exchange
- INTU Nasdaq
- AZN Nasdaq
- Market Cap
- INTU 183.8B
- AZN 212.2B
- IPO Year
- INTU 1993
- AZN 1993
- Fundamental
- Price
- INTU $643.39
- AZN $65.35
- Analyst Decision
- INTU Buy
- AZN Buy
- Analyst Count
- INTU 21
- AZN 10
- Target Price
- INTU $726.45
- AZN $88.80
- AVG Volume (30 Days)
- INTU 1.8M
- AZN 5.6M
- Earning Date
- INTU 02-20-2025
- AZN 02-06-2025
- Dividend Yield
- INTU 0.60%
- AZN 2.27%
- EPS Growth
- INTU 12.51
- AZN 9.79
- EPS
- INTU 10.28
- AZN 4.15
- Revenue
- INTU $16,590,000,000.00
- AZN $51,206,000,000.00
- Revenue This Year
- INTU $14.50
- AZN $17.69
- Revenue Next Year
- INTU $12.37
- AZN $7.95
- P/E Ratio
- INTU $62.58
- AZN $30.78
- Revenue Growth
- INTU 12.48
- AZN 13.81
- 52 Week Low
- INTU $557.29
- AZN $60.47
- 52 Week High
- INTU $714.78
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- INTU 46.91
- AZN 41.89
- Support Level
- INTU $653.98
- AZN $66.14
- Resistance Level
- INTU $679.85
- AZN $67.47
- Average True Range (ATR)
- INTU 17.57
- AZN 0.93
- MACD
- INTU -1.69
- AZN -0.03
- Stochastic Oscillator
- INTU 33.53
- AZN 30.45
About INTU Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of US market share for small-business accounting and do-it-yourself tax-filing software.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.